Trial Profile
A Non-inferiority Comparison of 35 mg Delayed-release Risedronate, Given Once-weekly Either Before or After Breakfast, and 5 mg Immediate-release Risedronate, Given Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms Fantasia Phase III
- Sponsors Procter & Gamble; Warner Chilcott
- 01 Jan 2012 Results published in Osteoporosis International.
- 20 Sep 2011 Results assessing bone safety presented at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.
- 20 Jun 2011 Actual end date (Apr 2010) as reported by ClinicalTrials.gov.